199,898 Shares in Inhibrx, Inc. (NASDAQ:INBX) Acquired by Caption Management LLC

Caption Management LLC purchased a new position in Inhibrx, Inc. (NASDAQ:INBX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 199,898 shares of the company's stock, valued at approximately $3,078,000. Caption Management LLC owned 1.38% of Inhibrx at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of INBX. Exchange Traded Concepts LLC purchased a new position in Inhibrx in the fourth quarter worth about $148,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new stake in Inhibrx during the fourth quarter valued at about $348,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Inhibrx during the fourth quarter valued at $47,000. Rhumbline Advisers acquired a new stake in Inhibrx during the 4th quarter worth about $228,000. Finally, New York State Common Retirement Fund purchased a new position in Inhibrx in the fourth quarter valued at $53,000. 82.46% of the stock is owned by institutional investors.

Inhibrx Price Performance

Shares of INBX traded down $0.08 during mid-day trading on Friday, hitting $11.18. 77,931 shares of the company's stock were exchanged, compared to its average volume of 186,181. The business's 50 day moving average is $12.82 and its two-hundred day moving average is $13.80. Inhibrx, Inc. has a fifty-two week low of $10.80 and a fifty-two week high of $34.73.

Inhibrx (NASDAQ:INBX - Get Free Report) last issued its quarterly earnings results on Monday, March 17th. The company reported ($3.09) EPS for the quarter, missing the consensus estimate of ($2.88) by ($0.21). The company had revenue of $0.10 million for the quarter. On average, equities research analysts anticipate that Inhibrx, Inc. will post 104.88 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, JMP Securities reiterated a "market perform" rating on shares of Inhibrx in a report on Wednesday, January 22nd.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.